(Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Date of event requiring this shell company report France (Jurisdiction of incorporation or organization) * Not for trading, but only in connection with the registration of the American Depositary Shares. Indicate the number of outstanding shares of common stock as of the close of the period covered by the annual report. Indicate by check mark whether the reg ...

Cellectis S.A. (NASDAQ:CLLS) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Bing Wang - Chief Financial Officer Mark Frattini - Chief Medical Officer Conference Call Participants Dev Prasad - Jefferies Gena Wang - Barclays Andrea Tan - Goldman Sachs Jack Allen - Baird Hartaj Singh - Oppenheimer & Company David Dai - SMBC Yanan Zhu - Wells Fargo Securities Brooke Schuster - William Blair Silvan Tuer ...

Allogene is developing ALLO-647, its proprietary anti-CD52 monoclonal antibody intended to enable expansion and persistence of AlloCAR T product candidates, including ALLO-501A. Allogene expects that the EXPAND trial, which is intended to demonstrate the contribution of ALLO-647 to the lymphodepletion regimen, will be open to enrollment early in the second quarter. ALLO-316, Allogene's first AlloCAR T candidate for solid tumors, targets CD70, an antigen expressed on clear cell renal cell carcinoma (RCC) and ...

Cellectis S.A. (NASDAQ:CLLS) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET Operator Company Participants | --- | |------------------------------------------| | | | Arthur Stril - Chief Business Officer | | Andre Choulika - Chief Executive Officer | | Mark Frattini - Chief Medical Officer | | Bing Wang - Chief Financial Officer | | Conference Call Participants | | Gena Wang - Barclays | | Jack Allen - Baird | | Yigal Nochomovitz - Citigroup | | Salveen Richter - Goldman Sachs | | David Dai - S ...

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and nine-month period ended September 30, 2022, included herein, have been prepared in accordance with International Accounting Standard 34 ("IAS 34")– Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to "$" and "U.S. dollars mean U.S. dollars and all refe ...

Cellectis S.A. (NASDAQ:CLLS) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Bing Wang - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Ashiq Mubarack - Citi Hartaj Singh - Oppenheimer Jack Allen - Baird David Dai - SMBC Silvan Tuerkcan - JMP Securities Nicolas Abbott - Wells Fargo Operator Good morning, everyone, and welcome to the Cellectis Second Quarter 2020 Earnings ...

Exhibit 99.1 PRELIMINARY NOTE The unaudited condensed Consolidated Financial Statements for the three and six-months periods ended June 30, 2022, included herein, have been prepared in accordance with International Accounting Standard 34 ("IAS 34")– Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). The consolidated financial statements are presented in U.S. dollars. All references in this interim report to "$" and "U.S. dollars mean U.S. dollars and all referenc ...

| --- | --- | --- | --- | |----------------------------------------|-------|-------|-------| | | | | | | | | | | | Commitment to a Cure | | | | | | | | | | Corporate Presentation May 2022 | | | | | | | | | | NASDAQ: CLLS EURONEXT GROWTH: ALCLS.PA | | | | | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Cellectis S.A. (NASDAQ:CLLS) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Â Company Participants | --- | --- | --- | |-------|-------|-------------------------------------------| | | | | | | | Arthur Stril - Chief Business Officer | | | | Andre Choulika - Chief Executive Officer | | | | Carrie Brownstein - Chief Medical Officer | | | | Bing Wang - Chief Financial Officer | | | | Conference Call Participants | | | | Gena Wang - Barclays | | | | Yigal Nochomovitz - Citigroup | | | | Kelly Shi - Je ...

EXHIBIT 99.1 Calyxt, Inc., Cellectis' Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop lifesaving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company and a majority-owned subsidiary of Cellectis, released today financial results f ...